JP2019534247A - ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 - Google Patents

ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 Download PDF

Info

Publication number
JP2019534247A
JP2019534247A JP2019512681A JP2019512681A JP2019534247A JP 2019534247 A JP2019534247 A JP 2019534247A JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019512681 A JP2019512681 A JP 2019512681A JP 2019534247 A JP2019534247 A JP 2019534247A
Authority
JP
Japan
Prior art keywords
nrp
nnif
seq
net
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019512681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534247A5 (https=
Inventor
クリスチャン コン ヨースト
クリスチャン コン ヨースト
ガイ エイ ツィマーマン
ガイ エイ ツィマーマン
アンドリュー エス ウェイリッチ
アンドリュー エス ウェイリッチ
ジョシュア シフマン
ジョシュア シフマン
Original Assignee
ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション, ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション filed Critical ザ ユニヴァーシティ オブ ユタ リサーチ ファウンデーション
Publication of JP2019534247A publication Critical patent/JP2019534247A/ja
Publication of JP2019534247A5 publication Critical patent/JP2019534247A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019512681A 2016-09-02 2017-09-05 ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法 Pending JP2019534247A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US62/383,243 2016-09-02
US201762492019P 2017-04-28 2017-04-28
US62/492,019 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (2)

Publication Number Publication Date
JP2019534247A true JP2019534247A (ja) 2019-11-28
JP2019534247A5 JP2019534247A5 (https=) 2020-10-15

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512681A Pending JP2019534247A (ja) 2016-09-02 2017-09-05 ｎＮＩＦ及びｎＮＩＦ関連ペプチド、ならびに関連する方法

Country Status (13)

Country Link
US (1) US10857201B2 (https=)
EP (1) EP3506924A4 (https=)
JP (1) JP2019534247A (https=)
KR (1) KR20190045271A (https=)
CN (1) CN109937047A (https=)
AU (1) AU2017321965A1 (https=)
BR (1) BR112019004299A2 (https=)
CA (1) CA3035770A1 (https=)
MX (1) MX2019002479A (https=)
RU (1) RU2019109049A (https=)
SG (1) SG11201901830UA (https=)
WO (1) WO2018045371A2 (https=)
ZA (1) ZA201901942B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods
US20230158108A1 (en) * 2020-05-04 2023-05-25 University Of Utah Research Foundation Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160194365A1 (en) * 2013-07-08 2016-07-07 The University Of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COOLS-LARTIGUE, J. ET AL.: "Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 8, JPN6021030409, 1 August 2013 (2013-08-01), pages 3446 - 3458, XP055684654, ISSN: 0004807769, DOI: 10.1172/JCI67484 *

Also Published As

Publication number Publication date
EP3506924A2 (en) 2019-07-10
CA3035770A1 (en) 2018-03-08
RU2019109049A3 (https=) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
ZA201901942B (en) 2020-10-28
KR20190045271A (ko) 2019-05-02
MX2019002479A (es) 2019-09-19
WO2018045371A2 (en) 2018-03-08
BR112019004299A2 (pt) 2019-05-28
SG11201901830UA (en) 2019-03-28
RU2019109049A (ru) 2020-10-05
US20190201487A1 (en) 2019-07-04
WO2018045371A3 (en) 2018-04-12
CN109937047A (zh) 2019-06-25
AU2017321965A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
Jiang et al. Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction
Yost et al. Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation
Zhou et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury
US20230381290A1 (en) Methods for treatment of and prophylaxis against inflammatory disorders
Lehrer Primate defensins
EP2209485B1 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
Shirasuna et al. Nanosilica-induced placental inflammation and pregnancy complications: Different roles of the inflammasome components NLRP3 and ASC
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
AU4393600A (en) Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US8304389B2 (en) Methods of inhibiting cell death or inflammation in a mammal by administering a BCL protein
EP3017824A1 (en) Inhibitor of extracellular trap formation in leukocytes
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
WO2016056665A1 (ja) 白血球の細胞外トラップ形成の阻害剤
HK40004861A (zh) Nnif和nnif相关肽以及相关方法
Yeh et al. Cisd2 delays atrial aging via a modulation of calcium homeostasis that mitigates atrial myopathy
Olonisakin Stressed Erythrophagocytosis as a Modifier of the Innate Immune Response to Klebsiella pneumoniae
Dugan et al. Intelectin-2 is a broad-spectrum antimicrobial lectin
US20190092814A1 (en) Peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220627